Results 131 to 140 of about 8,601 (210)

Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. [PDF]

Support Care Cancer
Hoogland AI, Li X, Hu B, Irizarry-Arroyo N, Welniak T, Rodriguez Y, Jain MD, Oswald LB, Small BJ, Snider JT, Wade SW, Chavez JC, Khimani F, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Pidala JA, Logue J, Booth-Jones M, Mirza AS, Huang J, Locke FL, Jim HSL.   +24 more
europepmc   +1 more source

ZUMA-Standarddemographie

, 1977
openaire   +1 more source

Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves. [PDF]

Cureus
Burke OJ, Peruzzo N, Tul Ain Khan N, Kancharla P.   +3 more
europepmc   +1 more source

Regulatory challenges of personalized medicine in the real world: are the right patients being treated with CD19-targeting CAR T-cells? [PDF]

EMBO Mol Med
Sebe A, Hernani R, Müller-Berghaus J.
europepmc   +1 more source

CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges. [PDF]

Cancers (Basel)
Aljabali AAA, Obeid MA, Alqudah A, Hamzat Y, Alqudah A, Alzoubi L, Gammoh O, Qnais E, Mishra V, Mishra Y, Hatahet T, El-Tanani M.   +11 more
europepmc   +1 more source

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance. [PDF]

BMC Cancer
Tilch MK, Schmidt C, Trneny M, Giné E, Hermine O, Ohler A, Herold S, Hoster E, Jiang L, Pott C, Dreyling M, Hess G.   +11 more
europepmc   +1 more source

Intelligent immunotherapy: AI-driven optimization of CAR-T therapy in hematologic malignancies. [PDF]

iScience
Farhadzadeh F, Borji A, Aram C, Alishvandi A, Kamali MJ, Rahimi M.   +5 more
europepmc   +1 more source

Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation. [PDF]

Ann Hematol
Ng LCK, Tan JY, Ong SY, Nagarajan C, Poon MLM, Ho AYL, Lim FWI, Chen Y.   +7 more
europepmc   +1 more source

Development and validation of the SMART-BPPV: a multimedia learning module for BPPV education. [PDF]

BMC Med Educ
Ho AZJ, Jamaluddin SA, Johari AH, Othman IA.   +3 more
europepmc   +1 more source

Chimeric antigen receptor T‐cell therapy in diffuse large B‐cell lymphoma: Evaluating axicabtagene ciloleucel in the ZUMA‐7 trial

HemaSphere
Vadim Lesan, Cristian Munteanu
doaj   +1 more source